Exelixis Inc
EXEL
NASDAQ
Biotechnology
$51.24
USD
+0.63 (+1.24%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $12.52B
Volume 2.3M
Revenue
$2.44B
TTM
+9.2%
YoY
Gross Margin
96%
TTM
-0.1%
YoY
Net Income
$860.62M
TTM
+42.9%
YoY
Operating Cash Flow
$1.18B
TTM
+53.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 568.3 | 597.8 | 598.7 | 610.8 | 628.7 |
YoY Growth | -10.8% | +10.8% | +5.6% | +10.0% | +10.6% |
Cost of Revenue | 19.5 | 18.6 | 26.5 | 20.0 | 20.7 |
Gross Profit | 548.8 | 579.2 | 572.2 | 590.9 | 608.0 |
Selling, General & Administrative | 134.9 | 123.7 | 123.0 | 139.6 | 147.6 |
Other Operating Expenses | 0.0 | 19.8 | 0.7 | 0.0 | 0.0 |
Total Operating Expenses | 335.2 | 342.6 | 337.0 | 339.5 | 359.6 |
Operating Income | 213.6 | 236.5 | 235.2 | 251.3 | 248.4 |
EBITDA | 220.9 | 263.8 | 242.9 | 258.3 | 255.4 |
Other Income / Expense | 0.1 | -0.0 | 0.0 | 0.2 | 0.1 |
Total Other Income / Expense | 16.8 | 15.9 | 17.5 | 16.3 | 14.3 |
Income Before Income Taxes | 230.4 | 252.4 | 252.7 | 267.7 | 262.7 |
Income Taxes | 45.6 | 58.8 | 8.2 | 57.2 | 50.6 |
Net Income | 184.8 | 193.6 | 244.5 | 210.5 | 212.1 |
Consolidated Net Income / Loss | 184.8 | 193.6 | 244.5 | 210.5 | 212.1 |
Net Income Attributable to Common Shareholders | 184.8 | 193.6 | 244.5 | 210.5 | 212.1 |
Basic EPS | $0.68 | $0.72 | $0.92 | $0.81 | $0.85 |
Diluted EPS | $0.65 | $0.69 | $0.88 | $0.79 | $0.82 |
Basic Shares Outstanding | 272.6M | 268.4M | 266.5M | 258.3M | 250.8M |
Diluted Shares Outstanding | 284.4M | 278.5M | 276.3M | 267.3M | 259.7M |